200,000+ products from a single source!
sales@angenechem.com
204204-73-9 | Acetic acid, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]-, (2Z)-
CAS No: 204204-73-9 Catalog No: AG0029CE MDL No:
Product Description
Catalog Number:
AG0029CE
Chemical Name:
Acetic acid, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]-, (2Z)-
CAS Number:
204204-73-9
Molecular Formula:
C18H20FNO3S
Molecular Weight:
349.4197
IUPAC Name:
(2Z)-2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene]acetic acid
InChI:
InChI=1S/C18H20FNO3S/c19-14-4-2-1-3-13(14)17(18(23)11-5-6-11)20-8-7-15(24)12(10-20)9-16(21)22/h1-4,9,11,15,17,24H,5-8,10H2,(H,21,22)/b12-9-
InChI Key:
ZWUQVNSJSJHFPS-XFXZXTDPSA-N
SMILES:
OC(=O)/C=C\1/CN(CCC1S)C(c1ccccc1F)C(=O)C1CC1
Properties
Complexity:
534
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
349.115g/mol
Formal Charge:
0
Heavy Atom Count:
24
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
349.42g/mol
Monoisotopic Mass:
349.115g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
58.6A^2
Undefined Atom Stereocenter Count:
2
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.3
Literature
| Title | Journal |
|---|---|
| Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. | Thrombosis and haemostasis 20120601 |
| Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study. | Drug testing and analysis 20120201 |
| The intestine as an important contributor to prasugrel active metabolite formation in vivo. | Drug metabolism and disposition: the biological fate of chemicals 20110401 |
| Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. | Journal of clinical pharmacology 20110301 |
| In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. | Journal of thrombosis and haemostasis : JTH 20110301 |
| Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism. | Platelets 20110101 |
| Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. | Arteriosclerosis, thrombosis, and vascular biology 20101201 |
| Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. | Drug metabolism and disposition: the biological fate of chemicals 20100601 |
| Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. | Thrombosis and haemostasis 20100601 |
| The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. | European journal of clinical pharmacology 20100201 |
| Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. | Journal of clinical pharmacology 20090801 |
| Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis. | Journal of clinical pharmacology 20090801 |
| Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. | Xenobiotica; the fate of foreign compounds in biological systems 20090301 |
| Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. | Drugs & aging 20090101 |
| Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. | Journal of thrombosis and haemostasis : JTH 20081101 |
| The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. | Platelets 20080301 |
| The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. | Journal of thrombosis and haemostasis : JTH 20080201 |
| Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. | Drug metabolism and pharmacokinetics 20080101 |
| The disposition of prasugrel, a novel thienopyridine, in humans. | Drug metabolism and disposition: the biological fate of chemicals 20070701 |
| The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. | Thrombosis and haemostasis 20070701 |
| Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method. | Drug metabolism and disposition: the biological fate of chemicals 20070601 |
| Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. | Thrombosis and haemostasis 20050901 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.